vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and TSS, Inc. (TSSI). Click either name above to swap in a different company.
TSS, Inc. is the larger business by last-quarter revenue ($60.9M vs $37.2M, roughly 1.6× GYRE THERAPEUTICS, INC.). TSS, Inc. runs the higher net margin — 20.0% vs -3.7%, a 23.6% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 21.8%). TSS, Inc. produced more free cash flow last quarter ($15.8M vs $-5.8M). Over the past eight quarters, TSS, Inc.'s revenue compounded faster (95.8% CAGR vs 17.0%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
GYRE vs TSSI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $60.9M |
| Net Profit | $-1.4M | $12.2M |
| Gross Margin | 95.3% | 17.6% |
| Operating Margin | 0.3% | 1.5% |
| Net Margin | -3.7% | 20.0% |
| Revenue YoY | 33.4% | 21.8% |
| Net Profit YoY | -340.1% | 535.7% |
| EPS (diluted) | $-0.01 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | $60.9M | ||
| Q3 25 | $30.6M | $41.9M | ||
| Q2 25 | $26.8M | $44.0M | ||
| Q1 25 | $22.1M | $99.0M | ||
| Q4 24 | $27.9M | $50.0M | ||
| Q3 24 | $25.5M | $70.1M | ||
| Q2 24 | $25.2M | $12.2M | ||
| Q1 24 | $27.2M | $15.9M |
| Q4 25 | $-1.4M | $12.2M | ||
| Q3 25 | $5.9M | $-1.5M | ||
| Q2 25 | $1.6M | $1.5M | ||
| Q1 25 | $3.7M | $3.0M | ||
| Q4 24 | $569.0K | $1.9M | ||
| Q3 24 | $2.9M | $2.6M | ||
| Q2 24 | $4.5M | $1.4M | ||
| Q1 24 | $9.9M | $15.0K |
| Q4 25 | 95.3% | 17.6% | ||
| Q3 25 | 94.7% | 11.1% | ||
| Q2 25 | 95.7% | 17.8% | ||
| Q1 25 | 95.9% | 9.3% | ||
| Q4 24 | 95.8% | 14.4% | ||
| Q3 24 | 96.2% | 11.3% | ||
| Q2 24 | 96.9% | 37.3% | ||
| Q1 24 | 96.4% | 17.1% |
| Q4 25 | 0.3% | 1.5% | ||
| Q3 25 | 22.7% | -2.2% | ||
| Q2 25 | 8.1% | 5.1% | ||
| Q1 25 | 10.3% | 4.2% | ||
| Q4 24 | 2.4% | 0.0% | ||
| Q3 24 | 16.6% | 5.4% | ||
| Q2 24 | 12.7% | 14.0% | ||
| Q1 24 | 29.7% | 1.6% |
| Q4 25 | -3.7% | 20.0% | ||
| Q3 25 | 19.4% | -3.6% | ||
| Q2 25 | 5.9% | 3.4% | ||
| Q1 25 | 16.9% | 3.0% | ||
| Q4 24 | 2.0% | 3.8% | ||
| Q3 24 | 11.2% | 3.8% | ||
| Q2 24 | 18.0% | 11.5% | ||
| Q1 24 | 36.6% | 0.1% |
| Q4 25 | $-0.01 | $0.44 | ||
| Q3 25 | $0.03 | $-0.06 | ||
| Q2 25 | $0.00 | $0.06 | ||
| Q1 25 | $0.00 | $0.12 | ||
| Q4 24 | $0.00 | $0.08 | ||
| Q3 24 | $0.01 | $0.10 | ||
| Q2 24 | $0.01 | $0.06 | ||
| Q1 24 | $0.03 | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | $85.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $106.0M | $76.6M |
| Total Assets | $166.1M | $184.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | $85.5M | ||
| Q3 25 | $60.0M | $70.7M | ||
| Q2 25 | $54.4M | — | ||
| Q1 25 | $29.9M | — | ||
| Q4 24 | $26.7M | $23.2M | ||
| Q3 24 | $25.1M | $46.4M | ||
| Q2 24 | $25.1M | $8.3M | ||
| Q1 24 | $37.4M | $14.4M |
| Q4 25 | $106.0M | $76.6M | ||
| Q3 25 | $101.9M | $63.4M | ||
| Q2 25 | $92.0M | $9.5M | ||
| Q1 25 | $68.1M | $9.4M | ||
| Q4 24 | $63.3M | $7.1M | ||
| Q3 24 | $63.2M | $7.7M | ||
| Q2 24 | $60.4M | $5.2M | ||
| Q1 24 | $56.6M | $3.7M |
| Q4 25 | $166.1M | $184.9M | ||
| Q3 25 | $159.4M | $165.4M | ||
| Q2 25 | $152.6M | $139.5M | ||
| Q1 25 | $129.8M | $113.5M | ||
| Q4 24 | $125.4M | $96.6M | ||
| Q3 24 | $125.2M | $67.3M | ||
| Q2 24 | $120.9M | $28.9M | ||
| Q1 24 | $122.0M | $26.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $16.3M |
| Free Cash FlowOCF − Capex | $-5.8M | $15.8M |
| FCF MarginFCF / Revenue | -15.5% | 25.9% |
| Capex IntensityCapex / Revenue | 0.4% | 0.9% |
| Cash ConversionOCF / Net Profit | — | 1.34× |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | $2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $16.3M | ||
| Q3 25 | $4.7M | $-18.4M | ||
| Q2 25 | $2.1M | $16.3M | ||
| Q1 25 | $-129.0K | $20.6M | ||
| Q4 24 | $-2.8M | $-21.6M | ||
| Q3 24 | $1.7M | $38.6M | ||
| Q2 24 | $-5.5M | $-4.3M | ||
| Q1 24 | $2.9M | $2.6M |
| Q4 25 | $-5.8M | $15.8M | ||
| Q3 25 | $4.0M | $-24.9M | ||
| Q2 25 | $1.8M | $5.4M | ||
| Q1 25 | $-251.0K | $5.8M | ||
| Q4 24 | $-2.8M | $-28.4M | ||
| Q3 24 | $1.0M | $38.6M | ||
| Q2 24 | $-6.9M | $-6.0M | ||
| Q1 24 | $2.7M | $2.6M |
| Q4 25 | -15.5% | 25.9% | ||
| Q3 25 | 13.1% | -59.3% | ||
| Q2 25 | 6.8% | 12.3% | ||
| Q1 25 | -1.1% | 5.8% | ||
| Q4 24 | -10.1% | -56.7% | ||
| Q3 24 | 4.1% | 55.1% | ||
| Q2 24 | -27.5% | -49.4% | ||
| Q1 24 | 9.8% | 16.4% |
| Q4 25 | 0.4% | 0.9% | ||
| Q3 25 | 2.2% | 15.3% | ||
| Q2 25 | 1.0% | 24.8% | ||
| Q1 25 | 0.6% | 15.0% | ||
| Q4 24 | 0.2% | 13.4% | ||
| Q3 24 | 2.7% | 0.1% | ||
| Q2 24 | 5.8% | 13.8% | ||
| Q1 24 | 0.9% | 0.2% |
| Q4 25 | — | 1.34× | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 1.32× | 11.02× | ||
| Q1 25 | -0.03× | 6.93× | ||
| Q4 24 | -4.85× | -11.32× | ||
| Q3 24 | 0.60× | 14.60× | ||
| Q2 24 | -1.21× | -3.09× | ||
| Q1 24 | 0.29× | 176.40× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GYRE
Segment breakdown not available.
TSSI
| Procurement Revenues Segment | $43.2M | 71% |
| System Integration Services Segment | $14.2M | 23% |
| Facilities Segment | $3.5M | 6% |
